Europe
Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted.
Sanofi and Regeneron halted a Phase III study of its checkpoint inhibitor Libtayo as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.
With emergency approval, the Oxford University researchers believe they could have a few million doses of the vaccine available by September if it is proven effective.
Two specific cell types in the nose have been identified as likely initial infection points for COVID-19 coronavirus.
Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.
Company enters next development phase with management expansion and implementation of a Strategic and Scientific Advisory Board
Heidelberg Pharma AG announces that it has successfully raised approximately EUR 14.4 million in gross proceeds through a private placement via an accelerated book building transaction.
Avadel Pharma announced positive topline data from its pivotal Phase III REST-ON clinical trial of FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
Free Lonza webinar to discuss the benefits of using physiologically relevant 3D cell culture models to enhance respiratory research for diseases like COVID-19
PRESS RELEASES